Otsuka Seeks Re-Examination Of Abilify Patent Due To Error In Original Filing

Law360, New York (September 6, 2004, 12:00 AM EDT) -- Japanese drug maker Otsuka Pharmaceutical Co. has filed a request with the U.S. Patent and Trademark Office for a re-examination of the basic U.S. composition of matter patent covering Abilify (aripiprazole), an antipsychotic agent marketed for the treatment of schizophrenia in the U.S. by its partner Bristol-Myers Squibb Co.

Otsuka filed the request after discovering that the original patent application contained an error in that the description of a prior art reference was identified by the wrong patent number, Bristol-Myers said in an 8-K regulatory filing...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.